Analysis of interleukin (IL)-1β IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders

Massimo Libra, Katia Mangano, Massimiliano Anzaldi, Cinzia Quattrocchi, Marco Donia, Roberto Di Marco, Santo Signorelli, Guido Scalia, Anna L. Zignego, Valli De Re, Maria C. Mazzarino, Ferdinando Nicoletti

Research output: Contribution to journalArticle

Abstract

Hepatitis C virus (HCV) causes hepatitis, liver cirrhosis and hepatocellular carcinoma, and may also induce type II mixed cryoglobulinemia syndrome (MC), a disease characterized by clonal B-cell lymphoproliferations that can evolve into non-Hodgkin's lymphoma (NHL). Interleukin-1 (IL-1) is a cytokine that plays an important role in initiating the cascade of events of immunoinflammatory responses through costimulation of T lymphocytes, B-cell proliferation, induction of adhesion molecules and stimulation of the production of other inflammatory cytokines. The role of IL-1 in immunoinflammatory responses is highlighted by the presence of endogenous regulators (IL-1 receptor antagonist, soluble receptors type 1 and II, human IL-1 accessory protein) that, when secreted into the blood stream may serve as endogenous regulators of IL-1 action. The aim of this study was to evaluate whether abnormalities in the blood levels of IL-1β IL-1 receptor antagonist, soluble IL-1 receptor type II and human IL-1 accessory protein in HCV+ patients are associated with development of MC and/or NHL. Relative to healthy controls, we observed: i) an increase in the circulating levels of IL-1β in HCV+ patients simultaneously affected by NHL; ii) increased levels of IL-1 accessory protein in patients singly infected by HCV; iii) increase of IL-1 receptor antagonist in HCV+ patients and in those affected also by NHL with or without MC; iv) a homogeneous increase of sIL- 1R type II in all the subgroup of patients. These data indicate that an attempt to increased circulating levels of IL-1 inhibitors occurs at different extent in the course of HCV infection as well as in its progression to NHL and/or MC.

Original languageEnglish
Pages (from-to)1305-1308
Number of pages4
JournalOncology Reports
Volume15
Issue number5
Publication statusPublished - May 2006

Keywords

  • Interleukin-1
  • Mixed cryoglobulinemia syndrome
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Analysis of interleukin (IL)-1β IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders'. Together they form a unique fingerprint.

  • Cite this

    Libra, M., Mangano, K., Anzaldi, M., Quattrocchi, C., Donia, M., Di Marco, R., Signorelli, S., Scalia, G., Zignego, A. L., De Re, V., Mazzarino, M. C., & Nicoletti, F. (2006). Analysis of interleukin (IL)-1β IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncology Reports, 15(5), 1305-1308.